A research team at Deciphera Pharmaceuticals LLC has discovered novel small-molecule colony-stimulating factor 1 receptor (CSF-1R) inhibitors for the treatment of cancer.
Virtici LLC has been granted a Small Business Innovation Research (SBIR) award by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to advance VTC-886, a first-in-class small molecule for the prevention of Porphyromonas gingivalis infection.
Researchers from Almirall SA and affiliated organizations reported the discovery and preclinical characterization of LAS-200813, a novel peptide inhibitor of the Keap1-Nrf2 protein-protein interaction.
A germline change in a single nucleotide increased the risk by up to 6-fold of developing an isocitrate dehydrogenase (IDH) mutant low-grade glioma. The rs55705857 genotype could serve as a biomarker before surgery to identify an early glioma.
By independently manipulating the lifespan of worms and one of its purported biomarkers, namely, the cessation of vigorous movement (CVM), investigators at the Center for Genomic Regulation (CRG) in Barcelona have demonstrated that the two are driven by partly independent processes.
Transcenta Holding Ltd. has received IND clearance from the FDA for TST-004, its best-in-class, humanized monoclonal antibody targeting mannose-binding protein-associated serine protease 2 (MASP2), for IgA nephropathy (IgAN).
Additional early-stage research and drug discovery news in brief, from: CSL, Elicio Therapeutics, Enzolytics, Innovation Pharmaceuticals, Lumen Bioscience, Nanology.
Lifearc and Provincial Health Services Authority (PHSA) have presented 7-morpholino-l,6-naphthyridin-5-yl derivatives acting as DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has patented glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, atherosclerosis, metabolic syndrome, stroke, nonalcoholic steatohepatitis and renal disorders, among other disorders.
Blueprint Medicines Corp. has divulged new EGFR mutant inhibitors, particularly EGFR L858R mutant and EGFR del746-750 mutant, reported to be useful for the treatment of non-small-cell lung cancer.
RSS
